CA2281838A1 - Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders - Google Patents
Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders Download PDFInfo
- Publication number
- CA2281838A1 CA2281838A1 CA002281838A CA2281838A CA2281838A1 CA 2281838 A1 CA2281838 A1 CA 2281838A1 CA 002281838 A CA002281838 A CA 002281838A CA 2281838 A CA2281838 A CA 2281838A CA 2281838 A1 CA2281838 A1 CA 2281838A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- cpg
- seq
- bases
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 68
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 41
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 41
- 108091029430 CpG site Proteins 0.000 title description 5
- 239000002158 endotoxin Substances 0.000 claims abstract description 117
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 69
- 102000004127 Cytokines Human genes 0.000 claims description 45
- 108090000695 Cytokines Proteins 0.000 claims description 45
- 108010065805 Interleukin-12 Proteins 0.000 claims description 32
- 102000013462 Interleukin-12 Human genes 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 230000028709 inflammatory response Effects 0.000 claims description 23
- 108090000174 Interleukin-10 Proteins 0.000 claims description 20
- 102000003814 Interleukin-10 Human genes 0.000 claims description 19
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 16
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 14
- 230000001154 acute effect Effects 0.000 claims description 11
- 239000013638 trimer Substances 0.000 claims description 10
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 claims description 8
- 229940104302 cytosine Drugs 0.000 claims description 8
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 7
- 229930024421 Adenine Natural products 0.000 claims description 7
- 229960000643 adenine Drugs 0.000 claims description 7
- 229940113082 thymine Drugs 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 8
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 4
- 229940104230 thymidine Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000004044 response Effects 0.000 abstract description 26
- 230000028993 immune response Effects 0.000 abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 208000019693 Lung disease Diseases 0.000 abstract description 7
- 230000001900 immune effect Effects 0.000 abstract description 5
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 123
- 108091034117 Oligonucleotide Proteins 0.000 description 94
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 48
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 45
- 210000004072 lung Anatomy 0.000 description 43
- 230000000694 effects Effects 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 30
- 235000013601 eggs Nutrition 0.000 description 30
- 229940117681 interleukin-12 Drugs 0.000 description 30
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- 239000012530 fluid Substances 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 210000003979 eosinophil Anatomy 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 230000004936 stimulating effect Effects 0.000 description 9
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 230000002101 lytic effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 210000003622 mature neutrocyte Anatomy 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000023504 respiratory system disease Diseases 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 206010069351 acute lung injury Diseases 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000011987 methylation Effects 0.000 description 5
- 238000007069 methylation reaction Methods 0.000 description 5
- -1 phosphorothioate modified oligonucleotides Chemical class 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 230000009325 pulmonary function Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000242680 Schistosoma mansoni Species 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000008718 systemic inflammatory response Effects 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 208000037487 Endotoxemia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 3
- 108010093965 Polymyxin B Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 206010049771 Shock haemorrhagic Diseases 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 3
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000001991 pathophysiological effect Effects 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 229920000024 polymyxin B Polymers 0.000 description 3
- 229960005266 polymyxin b Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000010398 acute inflammatory response Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010060921 Abdominal abscess Diseases 0.000 description 1
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 101100023365 Caenorhabditis elegans mif-2 gene Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101710200114 Cysteine proteinase inhibitor 10 Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010063593 DNA modification methylase SssI Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101150076458 ILI2 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 208000006816 Neonatal Sepsis Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BOKOVLFWCAFYHP-UHFFFAOYSA-N dihydroxy-methoxy-sulfanylidene-$l^{5}-phosphane Chemical compound COP(O)(O)=S BOKOVLFWCAFYHP-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- DHYWDEXXBWTTEH-UHFFFAOYSA-N odn 2007 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)C(O)C1 DHYWDEXXBWTTEH-UHFFFAOYSA-N 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3940597P | 1997-02-28 | 1997-02-28 | |
| US60/039,405 | 1997-02-28 | ||
| PCT/US1998/003678 WO1998037919A1 (en) | 1997-02-28 | 1998-02-25 | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2281838A1 true CA2281838A1 (en) | 1998-09-03 |
Family
ID=21905269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002281838A Abandoned CA2281838A1 (en) | 1997-02-28 | 1998-02-25 | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6214806B1 (https=) |
| EP (1) | EP1039935A4 (https=) |
| JP (1) | JP2001513776A (https=) |
| AU (1) | AU738513B2 (https=) |
| CA (1) | CA2281838A1 (https=) |
| WO (1) | WO1998037919A1 (https=) |
Families Citing this family (371)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7189834B2 (en) * | 1993-05-11 | 2007-03-13 | Marshall William E | Oligoribonucleotides alert the immune system of animals to the imminence of microbial infection |
| US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
| US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| GB2324093A (en) | 1996-01-04 | 1998-10-14 | Rican Limited | Helicobacter pylori bacterioferritin |
| US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| EP1003850B1 (en) | 1997-06-06 | 2009-05-27 | The Regents of the University of California | Inhibitors of dna immunostimulatory sequence activity |
| US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US7138384B1 (en) | 1997-08-29 | 2006-11-21 | The Regents Of The University Of California | Modulators of DNA cytosine-5 methyltransferase and methods for use thereof |
| JP4663113B2 (ja) * | 1997-09-05 | 2011-03-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用 |
| GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| JP2002514397A (ja) * | 1998-05-14 | 2002-05-21 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧオリゴヌクレオチドを用いる造血調節の方法 |
| CA2330916C (en) | 1998-05-19 | 2011-04-05 | Research Development Foundation | Triterpene compositions and methods for use thereof |
| SI1077722T1 (sl) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
| US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| PT1104306E (pt) | 1998-08-10 | 2006-05-31 | Antigenics Inc | Composicoes de cpg e adjuvantes de saponina e seus metodos |
| ATE326239T1 (de) * | 1998-09-18 | 2006-06-15 | Dynavax Tech Corp | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren |
| ES2572834T3 (es) | 1999-02-17 | 2016-06-02 | Csl Limited | Complejos inmunogénicos y métodos relacionados con los mismos |
| EP1156781B1 (en) | 1999-02-26 | 2005-06-08 | Chiron Corporation | Microemulsions with adsorbed macromolecules and microparticles |
| CA2371994C (en) | 1999-02-26 | 2010-09-28 | Guido Grandi | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
| EP1176966B1 (en) * | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| PT1187629E (pt) | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
| FR2797263B1 (fr) * | 1999-08-06 | 2003-09-19 | Pasteur Merieux Serums Vacc | Oligonucleotide immunostimulant |
| EP1196558A1 (fr) * | 1999-06-08 | 2002-04-17 | Aventis Pasteur | Oligonucleotide immunostimulant |
| AU5821000A (en) * | 1999-06-29 | 2001-01-31 | Smithkline Beecham Biologicals (Sa) | Vaccine |
| GB9915204D0 (en) * | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
| US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| ATE419869T1 (de) | 1999-08-19 | 2009-01-15 | Dynavax Tech Corp | Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür |
| NZ517929A (en) * | 1999-09-25 | 2004-02-27 | Univ Iowa Res Found | Immunostimulatory nucleic acids |
| US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| CA2397374A1 (en) * | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
| AU2001227889A1 (en) * | 2000-01-14 | 2001-07-24 | The United States of America, represented by The Secretary, Department of Health & Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| CA2398756A1 (en) * | 2000-01-31 | 2001-08-02 | Eyal Raz | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| AU4175101A (en) | 2000-02-23 | 2001-09-03 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
| US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
| US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
| US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| EP1296714B1 (en) | 2000-06-22 | 2009-08-26 | University Of Iowa Research Foundation | Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer. |
| WO2002002172A1 (en) * | 2000-06-30 | 2002-01-10 | Univ Jefferson | Dna palindrome - oligoguanylic acid compositions and uses thereof |
| KR100917101B1 (ko) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | 플렉시블 금속적층체 및 그 제조방법 |
| JP2005500806A (ja) * | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス |
| CA2881568C (en) | 2000-10-27 | 2019-09-24 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from streptococcus groups a & b |
| ES2307568T3 (es) * | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
| KR100881923B1 (ko) * | 2000-12-27 | 2009-02-04 | 다이나박스 테크놀로지 코퍼레이션 | 면역자극 폴리뉴클레오티드 및 그것의 사용 방법 |
| US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
| WO2002094845A2 (en) | 2001-05-21 | 2002-11-28 | Intercell Ag | Method for stabilising of nucleic acids |
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
| EP2423335B1 (en) * | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
| SK15762003A3 (sk) * | 2001-06-29 | 2005-01-03 | Chiron Corporation | Kompozícia vakcíny HCV E1E2 |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| US20030148316A1 (en) * | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
| US20030133988A1 (en) * | 2001-08-07 | 2003-07-17 | Fearon Karen L. | Immunomodulatory compositions, formulations, and methods for use thereof |
| WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| ATE411054T1 (de) * | 2001-08-17 | 2008-10-15 | Coley Pharm Gmbh | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
| JP4319908B2 (ja) | 2001-08-24 | 2009-08-26 | ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション | プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法 |
| JP2005501917A (ja) * | 2001-09-07 | 2005-01-20 | ザ トラスティーズ オブ ボストン ユニバーシティ | 免疫複合体関連疾患を処置するための方法および組成物 |
| DE60234375D1 (de) | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
| WO2003027313A2 (en) | 2001-09-24 | 2003-04-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| CN1633598A (zh) * | 2001-10-05 | 2005-06-29 | 科勒制药股份公司 | Toll样受体3信号传导的激动剂和拮抗剂 |
| US20030139364A1 (en) * | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| WO2003054161A2 (en) | 2001-12-20 | 2003-07-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| EP2572707A3 (en) | 2002-02-20 | 2013-11-06 | Novartis Vaccines and Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
| EP3006043B1 (en) * | 2002-04-04 | 2019-05-29 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
| KR100456681B1 (ko) * | 2002-05-22 | 2004-11-10 | 주식회사 대웅 | 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물 |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| US20040009949A1 (en) * | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
| US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| WO2004007743A2 (en) * | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
| WO2004011650A2 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| EP1575504A4 (en) * | 2002-08-01 | 2009-11-04 | Us Gov Health & Human Serv | METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES |
| RU2338750C2 (ru) * | 2002-08-19 | 2008-11-20 | Коли Фармасьютикал Груп, Инк. | ИММУНОСТИМУЛИРУЮЩИЕ ФОСФОРТИОАТНЫЕ CpG-ОЛИГОНУКЛЕОТИДЫ, СОДЕРЖАЩИЕ ФОСФОДИЭФИРНЫЕ СВЯЗИ, СПОСОБ ИММУНОМОДУЛЯЦИИ, СПОСОБ СТИМУЛИРОВАНИЯ ИММУННОГО ОТВЕТА |
| AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| WO2004024182A2 (en) | 2002-09-13 | 2004-03-25 | Intercell Ag | Method for isolating hepatitis c virus peptides |
| US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
| CN1753687A (zh) * | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
| WO2004098491A2 (en) * | 2002-11-01 | 2004-11-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES |
| US20040248837A1 (en) * | 2002-11-01 | 2004-12-09 | Eyal Raz | Methods of treating pulmonary fibrotic disorders |
| EP1562982B1 (en) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unexpected surface proteins in neisseria meningitidis |
| US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US8039443B2 (en) * | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US20050124565A1 (en) * | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| CA2502015A1 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5' cpg nucleic acids and methods of use |
| WO2004052293A2 (en) * | 2002-12-11 | 2004-06-24 | Hawaii Biotech, Inc. | Recombinant vaccine against flavivirus infection |
| JP5102959B2 (ja) | 2002-12-23 | 2012-12-19 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激配列オリゴヌクレオチド及びその使用方法 |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| EP1608402B1 (en) | 2003-03-24 | 2010-10-20 | Intercell AG | Improved vaccines |
| AU2004226605A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| JP2007525177A (ja) | 2003-04-21 | 2007-09-06 | アーケミックス コーポレイション | 血小板由来増殖因子に対する安定化アプタマーおよび腫瘍治療剤としてのそれらの使用 |
| KR100872472B1 (ko) * | 2003-05-15 | 2008-12-05 | 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 | 면역자극제 |
| EP1633778B1 (en) | 2003-06-05 | 2013-09-11 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Poly-gamma-glutamic acid conjugates for eliciting immune responses directed against bacilli |
| MXPA05013922A (es) * | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| EP1678303A2 (en) * | 2003-10-30 | 2006-07-12 | Coley Pharmaceutical GmbH | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
| US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
| US7973016B2 (en) * | 2004-01-23 | 2011-07-05 | Joslin Diebetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
| JP2007526253A (ja) * | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 免疫刺激性ウイルスｒｎａオリゴヌクレオチド |
| WO2005086835A2 (en) * | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics |
| US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
| US7579450B2 (en) * | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
| CN1989439B (zh) * | 2004-05-06 | 2010-12-29 | 美国政府健康及人类服务部 | 治疗葡萄膜炎的方法以及组合物 |
| US20060287263A1 (en) * | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing antigen-specific immune responses |
| EP2149583B1 (en) | 2004-09-24 | 2015-10-28 | Novartis AG | Modified VP1-capsid protein of parvovirus B19 |
| CA2587084C (en) | 2004-10-08 | 2019-07-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonym ous codons |
| MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| EP2436391A3 (en) | 2004-11-02 | 2012-07-04 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| WO2006065751A2 (en) | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
| WO2006081259A2 (en) | 2005-01-27 | 2006-08-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| US20080009455A9 (en) * | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
| JP2008535859A (ja) * | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 感染症によって悪化した喘息を治療するための方法 |
| AU2006241149A1 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
| ATE502954T1 (de) | 2005-06-14 | 2011-04-15 | Protox Therapeutics Inc | Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine |
| US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
| CA2613442C (en) | 2005-06-30 | 2016-08-23 | Archemix Corp. | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
| ATE439135T1 (de) | 2005-07-01 | 2009-08-15 | Index Pharmaceuticals Ab | Modulierung der reaktion auf steroide |
| AU2006266503B2 (en) | 2005-07-01 | 2011-12-08 | Index Pharmaceuticals Ab | Immunostimulatory method |
| KR20080030656A (ko) * | 2005-07-07 | 2008-04-04 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법 |
| US20080206276A1 (en) * | 2005-07-08 | 2008-08-28 | Michael Otto | Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections |
| CN101321868A (zh) * | 2005-09-16 | 2008-12-10 | 科利制药公司 | 通过核苷酸修饰调节短干扰核糖核酸(siRNA)的免疫刺激特性 |
| US20090214578A1 (en) * | 2005-09-16 | 2009-08-27 | Coley Pharmaceutical Gmbh | Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone |
| US20070081972A1 (en) * | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
| AU2006306805A1 (en) * | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
| JP4538522B2 (ja) * | 2005-11-25 | 2010-09-08 | コーリー ファーマシューティカル ゲーエムベーハー | 免疫刺激性オリゴリボヌクレオチド |
| CA2636139A1 (en) | 2005-12-14 | 2007-06-21 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| DK2405002T3 (en) | 2006-02-15 | 2015-01-05 | Adiutide Pharmaceuticals Gmbh | Compositions and methods for oligonukleotidformuleringer |
| EP2441469A1 (en) | 2006-03-14 | 2012-04-18 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
| EP2017281A4 (en) | 2006-04-14 | 2012-03-14 | Kyowa Hakko Kirin Co Ltd | AGONISTS AT TOLL-LIKE RECEPTOR 9 |
| US20070243290A1 (en) * | 2006-04-18 | 2007-10-18 | Melody Thompson | Method of tailoring infant formulas to individual nutritional needs prior to use |
| US8541559B2 (en) | 2006-06-12 | 2013-09-24 | Cytos Biotechnology Ag | Process for producing aggregated oligonucleotides |
| PT2078080E (pt) | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
| AU2007353120A1 (en) * | 2006-10-26 | 2008-11-20 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
| DK2444807T3 (da) | 2006-11-01 | 2014-08-11 | Ventana Med Syst Inc | Mono- og dinitropyrazolhaptenkonjugater |
| US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
| WO2008106551A2 (en) | 2007-02-28 | 2008-09-04 | The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. | Brachyury polypeptides and methods for use |
| WO2008131074A1 (en) | 2007-04-19 | 2008-10-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders |
| US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
| US8320302B2 (en) | 2007-04-20 | 2012-11-27 | Elster Electricity, Llc | Over the air microcontroller flash memory updates |
| CA2687441A1 (en) * | 2007-05-17 | 2008-11-27 | Coley Pharmaceutical Group, Inc. | Class a oligonucleotides with immunostimulatory potency |
| US9200287B2 (en) * | 2007-05-18 | 2015-12-01 | Adiutide Pharmaceuticals Gmbh | Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| WO2008147956A2 (en) * | 2007-05-25 | 2008-12-04 | Centocor, Inc. | Toll-like receptor 3 modulators and uses thereof |
| CN101820908A (zh) * | 2007-10-09 | 2010-09-01 | 科利制药公司 | 包含改性糖部分的免疫刺激寡核苷酸类似物 |
| EP2219671A4 (en) | 2007-11-09 | 2011-02-09 | Salk Inst For Biological Studi | USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS |
| EP3067048B1 (en) | 2007-12-07 | 2018-02-14 | GlaxoSmithKline Biologicals SA | Compositions for inducing immune responses |
| AU2009223613B2 (en) | 2008-03-10 | 2014-09-25 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
| WO2009143292A2 (en) | 2008-05-21 | 2009-11-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating pneumoconiosis with oligodeoxynucleotides |
| WO2009149013A2 (en) | 2008-06-05 | 2009-12-10 | Ventana Medical Systems, Inc. | Compositions comprising nanomaterials and method for using such compositions for histochemical processes |
| ES2569907T3 (es) | 2008-06-27 | 2016-05-13 | Zoetis Services Llc | Composiciones adyuvantes novedosas |
| JP2012503206A (ja) | 2008-09-22 | 2012-02-02 | オレゴン ヘルス アンド サイエンス ユニバーシティ | Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染を検出するための方法 |
| AU2009304552B2 (en) | 2008-10-16 | 2015-02-19 | Dalhousie University | Combination adjuvant formulation |
| BRPI0922561A2 (pt) | 2008-12-09 | 2020-08-11 | Pfizer Vaccines Llc | vacina de peptídeo de ch3 da ige. |
| WO2010099472A2 (en) | 2009-02-27 | 2010-09-02 | The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services | Spanx-b polypeptides and their use |
| CN103800906B (zh) | 2009-03-25 | 2017-09-22 | 德克萨斯大学系统董事会 | 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 |
| US20120052088A1 (en) | 2009-04-30 | 2012-03-01 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| BRPI1012036A2 (pt) | 2009-05-27 | 2017-10-10 | Selecta Biosciences Inc | nanocarreadores que possuem componentes com diferentes taxas de liberação |
| JP2013500326A (ja) | 2009-07-30 | 2013-01-07 | ファイザー バクシーンズ エルエルシー | 抗原性タウペプチドおよびその使用 |
| US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| JP2013502218A (ja) * | 2009-08-18 | 2013-01-24 | バクスター・インターナショナル・インコーポレイテッド | 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| WO2011027257A2 (en) | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| US8778683B2 (en) | 2009-10-07 | 2014-07-15 | Uvic Industry Partnerships Inc. | Vaccines comprising heat-sensitive transgenes |
| WO2011047340A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine |
| CN102713629B (zh) | 2009-11-20 | 2016-02-24 | 俄勒冈健康科学大学 | 用于检测结核分枝杆菌感染的方法 |
| RU2581020C2 (ru) | 2009-12-22 | 2016-04-10 | Селлдекс Терапьютикс, Инк. | Композиции вакцин |
| WO2011112599A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary. Department Of Health & Human Services | Immunogenic pote peptides and methods of use |
| TR201802933T4 (tr) | 2010-03-30 | 2018-03-21 | Childrens Hospital & Res Center At Oakland | Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi. |
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| US8895017B2 (en) | 2010-06-07 | 2014-11-25 | Pfizer Inc. | HER-2 peptides and vaccines |
| US8883171B2 (en) | 2010-09-14 | 2014-11-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
| US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
| WO2012109675A1 (en) | 2011-02-11 | 2012-08-16 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
| US10941399B2 (en) * | 2011-04-14 | 2021-03-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction |
| FR2975600B1 (fr) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| CA2837227C (en) | 2011-06-01 | 2022-05-10 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| WO2012167053A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| US9580475B2 (en) | 2011-06-20 | 2017-02-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for H1N1 influenza |
| KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
| WO2013039792A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunogens based on an hiv-1 gp120 v1v2 epitope |
| WO2013049535A2 (en) | 2011-09-30 | 2013-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Influenza vaccine |
| CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| EP3269728B1 (en) | 2011-10-20 | 2020-12-16 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
| CA3208225A1 (en) | 2012-01-16 | 2013-07-25 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatitic diseases and disorders |
| US12268718B2 (en) | 2012-01-16 | 2025-04-08 | Labyrinth Holdings Llc | Control of cellular redox levels |
| WO2013119683A1 (en) | 2012-02-07 | 2013-08-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses |
| CA2863949C (en) | 2012-02-13 | 2021-06-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| CA2866185C (en) | 2012-03-23 | 2021-04-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pathogenic phlebovirus isolates and compositions and methods of use |
| RU2737765C2 (ru) | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
| EP2852405B1 (en) | 2012-05-23 | 2019-03-13 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof |
| CN104428008B (zh) | 2012-05-24 | 2020-10-09 | 美国政府(由卫生和人类服务部的部长所代表) | 多价脑膜炎球菌缀合物及制备缀合物的方法 |
| WO2013192144A2 (en) | 2012-06-19 | 2013-12-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Rift valley fever virus replicon particles and use thereof |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| JP2015535829A (ja) | 2012-09-21 | 2015-12-17 | マッケーナ、エリザベス | 天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用 |
| WO2014052453A1 (en) * | 2012-09-25 | 2014-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
| US20160083698A1 (en) | 2013-04-19 | 2016-03-24 | The Regents Of The University Of California | Lone star virus |
| JP2016520077A (ja) | 2013-05-15 | 2016-07-11 | ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
| UA130246C2 (uk) | 2013-09-19 | 2025-12-31 | Зоетіс Сервісіз Ллс | Ад'ювант на основі олії |
| ES2957209T3 (es) | 2013-09-30 | 2024-01-15 | Triad Nat Security Llc | Polipéptidos inmunogénicos mosaicos del VIH de región conservada |
| WO2015063647A1 (en) | 2013-11-01 | 2015-05-07 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
| JP6758185B2 (ja) | 2013-12-13 | 2020-09-23 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | マルチエピトープｔａｒｐペプチドワクチンおよびその使用 |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN110859957B (zh) | 2014-01-21 | 2024-04-12 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| BR112016015835B1 (pt) | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| PL3096786T3 (pl) | 2014-01-21 | 2021-11-08 | Pfizer Inc. | Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty |
| WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
| CA2986096A1 (en) | 2014-05-30 | 2015-12-03 | Sanofi Pasteur Inc. | Expression and conformational analysis of engineered influenza hemagglutinin |
| TR201908550T4 (tr) | 2014-06-04 | 2019-07-22 | Exicure Inc | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. |
| EP3183251A4 (en) | 2014-08-22 | 2017-12-27 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| HUE062499T2 (hu) | 2015-01-15 | 2023-11-28 | Pfizer | Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények |
| CN115317600A (zh) | 2015-01-16 | 2022-11-11 | 硕腾服务有限责任公司 | 口蹄疫疫苗 |
| EP3256608A4 (en) | 2015-02-13 | 2019-02-20 | Icahn School of Medicine at Mount Sinai | RNA CONTAINING COMPOSITIONS AND METHODS OF USE |
| AU2016270979B2 (en) | 2015-06-02 | 2020-11-12 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| US10927151B2 (en) | 2015-06-09 | 2021-02-23 | Sanofi Pasteur Inc. | Methods of optimizing nucleotide sequences encoding engineered influenza proteins |
| US10954492B2 (en) | 2015-06-10 | 2021-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Processes for production and purification of nucleic acid-containing compositions |
| KR102225282B1 (ko) | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| WO2017011919A1 (en) | 2015-07-22 | 2017-01-26 | University Of Saskatchewan | Mycoplasma vaccines and uses thereof |
| CN107921113A (zh) | 2015-08-25 | 2018-04-17 | 巴比塔·阿格拉沃尔 | 免疫调节组合物及其使用方法 |
| EP3359651A1 (en) | 2015-10-05 | 2018-08-15 | THE UNITED STATES OF AMERICA, represented by the S | Human rota virus g9p[6]strain and use as a vaccine |
| EP4491735A3 (en) | 2015-10-08 | 2025-04-16 | The Governors of the University of Alberta | Hepatitis c virus e1/e2 heterodimers and methods of producing same |
| US11266726B2 (en) | 2015-10-30 | 2022-03-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of HER2-expressing solid tumors |
| JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
| MX2018008797A (es) | 2016-01-19 | 2018-11-29 | Pfizer | Vacunas contra el cancer. |
| WO2017189448A1 (en) | 2016-04-25 | 2017-11-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bivalent immunogenic conjugate for malaria and typhoid |
| EP3452598A4 (en) | 2016-05-06 | 2020-04-29 | Exicure, Inc. | LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA |
| US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
| CA3026096A1 (en) | 2016-06-02 | 2017-12-07 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| EA201892385A1 (ru) | 2016-06-03 | 2019-06-28 | Санофи Пастер Инк. | Модификация сконструированных полипептидов гемагглютинина вируса гриппа |
| US10947277B2 (en) | 2016-06-13 | 2021-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays |
| WO2018009603A1 (en) | 2016-07-08 | 2018-01-11 | The United State of America, as represented by the Secretary, Department of Health and Human Service | Chimeric west nile/zika viruses and methods of use |
| BR112018077540A2 (pt) | 2016-07-08 | 2019-10-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado |
| CA3031797A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA3031799A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US10172933B2 (en) | 2016-10-31 | 2019-01-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Mosaic vaccines for serotype a foot-and-mouth disease virus |
| BR112019014833A2 (pt) | 2017-01-20 | 2020-04-14 | Pfizer | composições imunogênicas para uso em vacinas pneumococais |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2019018744A1 (en) | 2017-07-21 | 2019-01-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS |
| US11235046B2 (en) | 2017-11-04 | 2022-02-01 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
| WO2019126197A1 (en) | 2017-12-18 | 2019-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacterial polysaccharide-conjugated carrier proteins and use thereof |
| JP2021506851A (ja) | 2017-12-19 | 2021-02-22 | マサチューセッツ インスティテュート オブ テクノロジー | 抗原−アジュバントカップリング試薬および使用の方法 |
| CN111629751B (zh) | 2018-01-22 | 2025-02-21 | 美国政府(由卫生和人类服务部的部长所代表) | 广泛保护性灭活流感病毒疫苗 |
| BR112020014978A2 (pt) | 2018-02-05 | 2020-12-22 | Sanofi Pasteur, Inc. | Composição de conjugado polissacarídeo-proteína pneumocócico multivalente |
| EP3749357A4 (en) | 2018-02-05 | 2022-04-20 | Sanofi Pasteur, Inc. | POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION |
| WO2019173438A1 (en) | 2018-03-06 | 2019-09-12 | Stc. Unm | Compositions and methods for reducing serum triglycerides |
| EP3774884B1 (en) | 2018-03-28 | 2023-12-06 | Sanofi Pasteur Inc. | Methods of generating broadly protective vaccine compositions comprising hemagglutinin |
| JP2021519600A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | 抗原性インフルエンザ−フェリチンポリペプチド |
| KR20210018205A (ko) | 2018-04-03 | 2021-02-17 | 사노피 | 항원성 OspA 폴리펩타이드 |
| JP7614841B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| WO2019195314A2 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic epstein barr virus polypeptides |
| WO2020014656A1 (en) | 2018-07-13 | 2020-01-16 | University Of Georgia Research Foundation | Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| KR20210124205A (ko) | 2018-12-04 | 2021-10-14 | 더 락커펠러 유니버시티 | Hiv 백신 면역원 |
| WO2020123777A1 (en) | 2018-12-12 | 2020-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins |
| CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| WO2020123989A1 (en) | 2018-12-14 | 2020-06-18 | University Of Georgia Research Foundation, Inc. | Crimean-congo hemorrhagic fever virus replicon particles and use thereof |
| CN114957407A (zh) | 2019-04-02 | 2022-08-30 | 赛诺菲 | 抗原性多聚呼吸道合胞病毒多肽 |
| WO2020208502A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| WO2021055580A2 (en) | 2019-09-18 | 2021-03-25 | Children's Medical Center Corporation | An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use |
| US20230000966A1 (en) | 2019-11-01 | 2023-01-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| BR112022010228A2 (pt) | 2019-12-17 | 2022-09-06 | Us Health | Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas |
| BR112022014555A2 (pt) | 2020-02-23 | 2022-09-20 | Pfizer | Composições de escherichia coli e métodos das mesmas. |
| US20230121059A1 (en) | 2020-02-28 | 2023-04-20 | Sanofi Pasteur Inc. | High dose flu vaccine in pediatric subjects |
| US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
| BR112022021258A2 (pt) | 2020-04-20 | 2023-01-17 | Univ Saskatchewan | Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| PE20231934A1 (es) | 2020-10-27 | 2023-12-01 | Pfizer | Composiciones de escherichia coli y metodos de las mismas |
| CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| JP7804673B2 (ja) | 2020-11-10 | 2026-01-22 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| EP4243833A4 (en) * | 2020-11-13 | 2025-08-27 | Guardian Therapeutics Llc | GPC3 APTAMERS, VARIANTS AND RELATED USE |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| US20240299510A1 (en) | 2020-12-31 | 2024-09-12 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
| US20240159738A1 (en) | 2021-03-16 | 2024-05-16 | Osaka University | Novel medical technique using follicular t-cells |
| US20240309051A1 (en) | 2021-03-16 | 2024-09-19 | Osaka University | Follicular helper t (tfh) cells specific to sars-cov-2 virus |
| JP2024521847A (ja) | 2021-05-28 | 2024-06-04 | ファイザー・インク | コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用 |
| MX2023013434A (es) | 2021-05-28 | 2023-12-12 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos. |
| WO2023288263A1 (en) | 2021-07-16 | 2023-01-19 | The Board Of Trustees Of The University Of Illinois | Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs |
| CN118176204A (zh) | 2021-08-11 | 2024-06-11 | 圣诺菲·帕斯图尔公司 | 截短的流感神经氨酸酶及其使用方法 |
| AU2022361432A1 (en) | 2021-10-08 | 2024-05-23 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
| AU2022379948A1 (en) | 2021-11-05 | 2024-06-20 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
| WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
| MX2024005462A (es) | 2021-11-05 | 2024-05-22 | Sanofi Sa | Vacuna de arn del virus respiratorio sincitial. |
| MX2024006506A (es) | 2021-11-30 | 2024-08-14 | Sanofi Pasteur Inc | Vacunas basadas en vectores virales de metapneumovirus humano. |
| JP2024542635A (ja) | 2021-11-30 | 2024-11-15 | サノフィ パスツール インコーポレイテッド | ヒトメタニューモウイルスワクチン |
| JP2025500880A (ja) | 2021-12-17 | 2025-01-15 | サノフイ | ライム病ｒｎａワクチン |
| CA3247998A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses |
| JP2025503207A (ja) | 2022-01-27 | 2025-01-30 | サノフィ・パスツール | 修飾されたＶｅｒｏ細胞、及びウイルス産生にこれを使用する方法 |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| EP4494146A1 (en) | 2022-03-14 | 2025-01-22 | Sanofi Pasteur, Inc. | Machine-learning techniques in protein design for vaccine generation |
| CA3256624A1 (en) | 2022-05-06 | 2023-11-09 | Sanofi | SIGNAL SEQUENCES FOR NUCLEIC ACID-BASED VACCINES |
| CA3256617A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES |
| KR20250099727A (ko) | 2022-11-04 | 2025-07-02 | 사노피 파스퇴르 인크 | 호흡기 세포융합 바이러스 rna 백신접종 |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| EP4622665A2 (en) | 2022-11-22 | 2025-10-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2023403045A1 (en) | 2022-12-01 | 2025-06-12 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| WO2024121380A1 (en) | 2022-12-08 | 2024-06-13 | Pierre Fabre Medicament | Vaccinal composition and adjuvant |
| AU2023393199A1 (en) | 2022-12-13 | 2025-05-29 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
| EP4637813A1 (en) | 2022-12-20 | 2025-10-29 | Sanofi Pasteur | Rhinovirus mrna vaccine |
| WO2024163327A1 (en) | 2023-01-30 | 2024-08-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN120813371A (zh) | 2023-03-02 | 2025-10-17 | 赛诺菲巴斯德有限公司 | 用于在衣原体病的治疗中使用的组合物 |
| PE20252774A1 (es) | 2023-03-30 | 2025-12-22 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos |
| AU2024255922A1 (en) | 2023-04-14 | 2025-10-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US12502424B2 (en) | 2023-05-05 | 2025-12-23 | Sanofi Pasteur Inc. | Compositions for use in treatment of acne |
| WO2024231565A1 (en) | 2023-05-10 | 2024-11-14 | Sanofi | Combination respiratory mrna vaccines |
| US20240398932A1 (en) | 2023-05-11 | 2024-12-05 | Sanofi Pasteur Inc. | Respiratory syncytial virus vaccine and methods of use |
| KR20260015203A (ko) | 2023-05-19 | 2026-02-02 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법 |
| CN121620357A (zh) | 2023-06-01 | 2026-03-06 | 赛诺菲巴斯德有限公司 | 包含mRNA脂质纳米颗粒的热稳定组合物 |
| EP4735028A1 (en) | 2023-06-30 | 2026-05-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine |
| AU2024291595A1 (en) | 2023-07-19 | 2026-03-05 | Sanofi | Porphyromonas gingivalis antigenic constructs |
| WO2025051975A1 (en) | 2023-09-06 | 2025-03-13 | Sanofi | Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| TW202535439A (zh) | 2023-11-17 | 2025-09-16 | 美商賽諾菲巴斯德公司 | 海藻糖疫苗調配物 |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025186459A1 (en) | 2024-03-08 | 2025-09-12 | Sanofi | Antigenic epstein barr virus polypeptides |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
| WO2025210592A1 (en) | 2024-04-05 | 2025-10-09 | Sanofi Pasteur Inc. | Muscle cell lnp-mrna quality control assays |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
| WO2025238502A1 (en) | 2024-05-14 | 2025-11-20 | Pfizer Inc. | Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof |
| WO2025257712A1 (en) | 2024-06-12 | 2025-12-18 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
| EP4670733A1 (en) | 2024-06-27 | 2025-12-31 | Sanofi | METHODS FOR PREPARING VIRAL PROTEINS AND THEIR USES |
| WO2026052773A1 (en) | 2024-09-06 | 2026-03-12 | Sanofi | Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| DE3280400D1 (de) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| CA1339596C (en) | 1987-08-07 | 1997-12-23 | New England Medical Center Hospitals, Inc. | Viral expression inhibitors |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5786189A (en) | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
| US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
| US5514577A (en) | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| ES2104717T3 (es) | 1990-08-16 | 1997-10-16 | Isis Pharmaceuticals Inc | Oligonucleotidos para modular los efectos de las infecciones por citomegalovirus. |
| CA2106386A1 (en) | 1991-04-18 | 1992-10-19 | Barbara C. F. Chu | Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences |
| JPH06507911A (ja) | 1991-05-31 | 1994-09-08 | ジンタ・インコーポレイテッド | 中性オリゴマーを経皮投与するための組成物及び供給系 |
| BR9306867A (pt) * | 1992-07-17 | 1998-12-08 | Aprogenex Inc | Enriquecimento e identificação de células fetais do sangue materno para a hibridização in situ |
| US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| EP0714308A4 (en) | 1993-08-26 | 1998-07-29 | Univ California | METHOD, COMPOSITIONS AND DEVICES FOR THE ADMINISTRATION OF NAKED POLYNUCLEOTIDS, WHICH ENCODE FOR BIOLOGICALLY ACTIVE PEPTIDES |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1167379A3 (en) * | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| WO1996002560A1 (en) * | 1994-07-18 | 1996-02-01 | University Of North Carolina At Chapel Hill | Oligonucleoside compounds and methods for inhibiting tumor growth, invasion and metastasis |
| ATE271128T1 (de) | 1995-05-11 | 2004-07-15 | Applied Research Systems | Inhibitoren der il-6 aktivitaet |
| US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
| CA2244946C (en) | 1996-01-30 | 2010-04-13 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| CN1258274A (zh) | 1997-06-05 | 2000-06-28 | 亨茨曼Ici化学品有限公司 | 制备氨基甲酸酯的方法 |
| EP1003850B1 (en) | 1997-06-06 | 2009-05-27 | The Regents of the University of California | Inhibitors of dna immunostimulatory sequence activity |
-
1998
- 1998-02-25 WO PCT/US1998/003678 patent/WO1998037919A1/en not_active Ceased
- 1998-02-25 CA CA002281838A patent/CA2281838A1/en not_active Abandoned
- 1998-02-25 AU AU66674/98A patent/AU738513B2/en not_active Ceased
- 1998-02-25 US US09/030,701 patent/US6214806B1/en not_active Expired - Fee Related
- 1998-02-25 JP JP53781098A patent/JP2001513776A/ja not_active Ceased
- 1998-02-25 EP EP98908714A patent/EP1039935A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1039935A4 (en) | 2005-04-27 |
| JP2001513776A (ja) | 2001-09-04 |
| EP1039935A1 (en) | 2000-10-04 |
| AU6667498A (en) | 1998-09-18 |
| WO1998037919A1 (en) | 1998-09-03 |
| AU738513B2 (en) | 2001-09-20 |
| US6214806B1 (en) | 2001-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU738513B2 (en) | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders | |
| KR100689942B1 (ko) | 면역자극 핵산분자 | |
| Pastore et al. | Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. | |
| EP1511845B1 (en) | Immunostimulatory oligonucleotides and uses thereof | |
| EP2901856B1 (en) | Immunostimulatory oligonucleotide multimers | |
| DE60029460T3 (de) | Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon | |
| EP1009413B1 (en) | Use of immunostimulatory oligonucleotides for preventing or treating asthma | |
| US20050250716A1 (en) | Immunostimulatory oligodeoxynucleotides | |
| JP2002514397A (ja) | ＣｐＧオリゴヌクレオチドを用いる造血調節の方法 | |
| EP2034015A1 (en) | Immunostimulatory oligonucleotide and pharmaceutical application thereof | |
| EP2269622B1 (en) | CpG oligonucleotides used for enhancing steroid activity in a steroid dependent patient | |
| Zhang et al. | Acute alcohol intoxication suppresses the CXC chemokine response during endotoxemia | |
| BR112015016420B1 (pt) | Composto de oligonucleotídeo imunorregulatório, composição farmacêutica e uso do composto iro ou da composição farmacêutica | |
| EP1904077B1 (en) | Modulating responsiveness to steroids | |
| Yamamoto et al. | Oligodeoxyribonucleotides with 5′-ACGT-3′ or 5′-TCGA-3′ sequence induce production of interferons | |
| Edelman et al. | Lipopolysaccharide stimulates alveolar macrophage adherence in vivo and in vitro | |
| Rodriguez et al. | Immunostimulatory PyNTTTTGT oligodeoxynucleotides: structural properties and refinement of the active motif | |
| Alam et al. | In Vivo Role of p38 Mitogen-Activated Protein Kinase in Mediating the Anti-inflammatory Effects of CpG... | |
| HK1211179B (en) | Immunostimulatory oligonucleotide multimers | |
| HK1098499A (en) | Immunostimulatory nucleic acid molecules | |
| HK1029515B (en) | Use of immunostimulatory oligonucleotides for preventing or treating asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |